Major diabetes, cardiac drugs to become up to 35% cheaper.

published on July 13, 2014

MUMBAI: In a move that has surprised and shaken the industry, prices of widely-used expensive anti-diabetic and cardiac medicines will reduce by as much as 35% over the next few weeks, with the drug pricing regulator, National Pharmaceutical Pricing Authority (NPPA), deciding to bring them under price control.

In a rare invocation of a lesser-used provision in the Drug Price Control Order (DPCO), NPPA has fixed the prices of 108 formulation packs of 50 anti-diabetic and cardiovascular medicines. What makes the development significant is that NPPA has fixed prices of those medicines which are not listed under the national list of essential medicines (NLEM). Prices of 652 drugs under NLEM were fixed by the government last year under DPCO 2013.

The drugs that will become cheaper include Gliclazide, Glimepiride, Sitagliptin, Voglibose, Amlodipine, Telmisartan and Rosuvastatin, Heparin and Ramipril.

The move will mean savings for patients prescribed expensive chronic therapies.

Read More : http://timesofindia.indiatimes.com/india/Major-diabetes-cardiac-drugs-to-become-up-to-35-cheaper/articleshow/38339283.cms

Read Also : Widely used drugs to cost up to 50% less.